Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients

Science Immunology

Volumn 1, Issue 2, 2016, Pages

  Condamine, Thomas ^a,h   Dominguez, George A ^a   Youn, Je In ^a,i   Kossenkov, Andrew V ^a   Mony, Sridevi ^a   Alicea Torres, Kevin ^a   Tcyganov, Evgenii ^a   Hashimoto, Ayumi ^a   Nefedova, Yulia ^a   Lin, Cindy ^a   Partlova, Simona ^a,j   Garfall, Alfred ^b   Vogl, Dan T ^b   Xu, Xiaowei ^b   Knight, Stella C ^c   Malietzis, George ^c,d   Lee, Gui Han ^c,d   Eruslanov, Evgeniy ^b   Albelda, Steven M ^b   Wang, Xianwei ^e   Mehta, Jawahar L ^e   Bewtra, Meenakshi ^b   Rustgi, Anil ^b   Hockstein, Neil ^f   Witt, Robert ^f   Masters, Gregory ^f   Nam, Brian ^f   Smirnov, Denis ^g   Sepulveda, Manuel A ^g   Gabrilovich, Dmitry I ^a   more..

^a WISTAR INSTITUTE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d ST MARK S HOSPITAL   (United Kingdom)

^e UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^f HELEN F GRAHAM CANCER CENTER   (United States)

^g JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^h Experimental Station   (United States)

ⁱ Seoul National University College of Medicine   (South Korea)

^j Sotio as   (Czech Republic)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85025478245     PISSN: None     EISSN: 24709468     Source Type: Journal    
DOI: 10.1126/sciimmunol.aaf8943     Document Type: Article

References (52)

1. T. Condamine, I. Ramachandran, J.-I. Youn, D. I. Gabrilovich, Regulation of tumor metastasis by myeloid-derived suppressor cells. Annu. Rev. Med. 66, 97–110 (2015).
2. M. N. Messmer, C. S. Netherby, D. Banik, S. I. Abrams, Tumor-induced myeloid dysfunction and its implications for cancer immunotherapy. Cancer Immunol. Immunother. 64, 1–13 (2015).
3. J. Finke, J. Ko, B. Rini, P. Rayman, J. Ireland, P. Cohen, MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy. Int. Immunopharmacol. 11, 856–861 (2011).
4. + monocytic myeloid-derived suppressor cells and their clinical relevance in non–small cell lung cancer. Am. J. Respir. Crit. Care Med. 186, 1025–1036 (2012).
5. E.-K. Vetsika, F. Koinis, M. Gioulbasani, D. Aggouraki, A. Koutoulaki, E. Skalidaki, D. Mavroudis, V. Georgoulias, A. Kotsakis, A circulating subpopulation of monocytic myeloid-derived suppressor cells as an independent prognostic/predictive factor in untreated non-small lung cancer patients. J. Immunol. Res. 2014, 659294 (2014).
6. + T lymphocytes in patients with advanced-stage non-small cell lung cancer. J. Cancer Res. Clin. Oncol. 136, 35–45 (2010).
7. C. M. Diaz-Montero, M. L. Salem, M. I. Nishimura, E. Garrett-Mayer, D. J. Cole, A. J. Montero, Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin–cyclophosphamide chemotherapy. Cancer Immunol. Immunother. 58, 49–59 (2009).
8. C. Meyer, L. Cagnon, C. M. Costa-Nunes, P. Baumgaertner, N. Montandon, L. Leyvraz, O. Michielin, E. Romano, D. E. Speiser, Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab. Cancer Immunol. Immunother. 63, 247–257 (2014).
9. A. A. Tarhini, H. Edington, L. H. Butterfield, Y. Lin, Y. Shuai, H. Tawbi, C. Sander, Y. Yin, M. Holtzman, J. Johnson, U. N. M. Rao, J. M. Kirkwood, Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab. PLOS One 9, e87705 (2014).
10. Z. Wang, Y. Zhang, Y. Liu, L. Wang, L. Zhao, T. Yang, C. He, Y. Song, Q. Gao, Association of myeloid-derived suppressor cells and efficacy of cytokine-induced killer cell immunotherapy in metastatic renal cell carcinoma patients. J. Immunother. 37, 43–50 (2014).
11. S. E. Finkelstein, T. Carey, I. Fricke, D. Yu, D. Goetz, M. Gratz, M. Dunn, P. Urbas, A. Daud, R. DeConti, S. Antonia, D. Gabrilovich, M. Fishman, Changes in dendritic cell phenotype after a new high-dose weekly schedule of interleukin-2 therapy for kidney cancer and melanoma. J. Immunother. 33, 817–827 (2010).
12. T. Kimura, J. R. McKolanis, L. A. Dzubinski, K. Islam, D. M. Potter, A. M. Salazar, R. E. Schoen, O. J. Finn, MUC1 vaccine for individuals with advanced adenoma of the colon: A cancer immunoprevention feasibility study. Cancer Prev. Res. 6, 18–26 (2013).
13. J.-I. Youn, S. Nagaraj, M. Collazo, D. I. Gabrilovich, Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J. Immunol. 181, 5791–5802 (2008).
14. I. Poschke, R. Kiessling, On the armament and appearances of human myeloid-derived suppressor cells. Clin. Immunol. 144, 250–268 (2012).
15. S. Mandruzzato, S. Brandau, C. M. Britten, V. Bronte, V. Damuzzo, C. Gouttefangeas, D. Maurer, C. Ottensmeier, S. H. van der Burg, M. J. P. Welters, S. Walter, Toward harmonized phenotyping of human myeloid-derived suppressor cells by flow cytometry: Results from an interim study. Cancer Immunol. Immunother. 65, 161–169 (2016).
16. T. Condamine, V. Kumar, I. R. Ramachandran, J.-I. Youn, E. Celis, N. Finnberg, W. S. El-Deiry, R. Winograd, R. H. Vonderheide, N. R. English, S. C. Knight, H. Yagita, J. C. McCaffrey, S. Antonia, N. Hockstein, R. Witt, G. Masters, T. Bauer, D. I. Gabrilovich, ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R–mediated apoptosis. J. Clin. Invest. 124, 2626–2639 (2014).
17. T. Condamine, J. Mastio, D. I. Gabrilovich, Transcriptional regulation of myeloid-derived suppressor cells. J. Leukoc. Biol. 98, 913–922 (2015).
18. N. Al-Banna, C. Lehmann, Oxidized LDL and LOX-1 in experimental sepsis. Mediators Inflamm. 2013, 761789 (2013).
19. T. Sawamura, N. Kume, T. Aoyama, H. Moriwaki, H. Hoshikawa, Y. Aiba, T. Tanaka, S. Miwa, Y. Katsura, T. Kita, T. Masaki, An endothelial receptor for oxidized low-density lipoprotein. Nature 386, 73–77 (1997).
20. A. Taye, A. A. K. El-Sheikh, Lectin-like oxidized low-density lipoprotein receptor 1 pathways. Eur. J. Clin. Invest. 43, 740–745 (2013).
21. R. Yoshimoto, Y. Fujita, A. Kakino, S. Iwamoto, T. Takaya, T. Sawamura, The discovery of LOX-1, its ligands and clinical significance. Cardiovasc. Drugs Ther. 25, 379–391 (2011).
22. I. Moldovan, J. Galon, I. Maridonneau-Parini, S. Roman Roman, C. Mathiot, W.-H. Fridman, C. Sautès-Fridman, Regulation of production of soluble Fcg receptors type III in normal and pathological conditions. Immunol. Lett. 68, 125–134 (1999).
23. A. Banerjee, N. K. Mondal, D. Das, M. R. Ray, Neutrophilic inflammatory response and oxidative stress in premenopausal women chronically exposed to indoor air pollution from biomass burning. Inflammation 35, 671–683 (2012).
24. J. L. Mehta, N. Sanada, C. P. Hu, J. Chen, A. Dandapat, F. Sugawara, H. Satoh, K. Inoue, Y. Kawase, K.-I. Jishage, H. Suzuki, M. Takeya, L. Schnackenberg, R. Beger, P. L. Hermonat, M. Thomas, T. Sawamura, Deletion of LOX-1 reduces atherogenesis in LDLR knockout mice fed high cholesterol diet. Circ. Res. 100, 1634–1642 (2007).
25. A. Pirillo, G. D. Norata, A. L. Catapano, LOX-1, OxLDL, and atherosclerosis. Mediators Inflamm. 2013, 152786 (2013).
26. C.-H. A. Tang, S. Ranatunga, C. L. Kriss, C. L. Cubitt, J. Tao, J. A. Pinilla-Ibarz, J. R. Del Valle, C.-C. Hu, Inhibition of ER stress-associated IRE-1/XBP-1 pathway reduces leukemic cell survival. J. Clin. Invest. 124, 2585–2598 (2014).
27. T. Sawamura, A. Kakino, Y. Fujita, LOX-1: A multiligand receptor at the crossroads of response to danger signals. Curr. Opin. Lipidol. 23, 439–445 (2012).
28. I. R. Ramachandran, A. Martner, A. Pisklakova, T. Condamine, T. Chase, T. Vogl, J. Roth, D. Gabrilovich, Y. Nefedova, Myeloid-derived suppressor cells regulate growth of multiple myeloma by inhibiting T cells in bone marrow. J. Immunol. 190, 3815–3823 (2013).
29. V. Kumar, S. Patel, E. Tcyganov, D. Gabrilovich, The nature of myeloid-derived suppressor cells in the tumor microenvironment. Trends Immunol. 37, 208–220 (2016).
30. D. I. Gabrilovich, S. Ostrand-Rosenberg, V. Bronte, Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 12, 253–268 (2012).
31. D. Marvel, D. I. Gabrilovich, Myeloid-derived suppressor cells in the tumor microenvironment: Expect the unexpected. J. Clin. Invest. 125, 3356–3364 (2015).
32. Z. G. Fridlender, J. Sun, I. Mishalian, S. Singhal, G. Cheng, V. Kapoor, W. Horng, G. Fridlender, R. Bayuh, G. S. Worthen, S. M. Albelda, Transcriptomic analysis comparing tumor-associated neutrophils with granulocytic myeloid-derived suppressor cells and normal neutrophils. PLOS One 7, e31524 (2012).
33. M. Holcik, N. Sonenberg, Translational control in stress and apoptosis. Nat. Rev. Mol. Cell Biol. 6, 318–327 (2005).
34. D. Ron, P. Walter, Signal integration in the endoplasmic reticulum unfolded protein response. Nat. Rev. Mol. Cell Biol. 8, 519–529 (2007).
35. N. Cláudio, A. Dalet, E. Gatti, P. Pierre, Mapping the crossroads of immune activation and cellular stress response pathways. EMBO J. 32, 1214–1224 (2013).
36. + T cell priming. PLOS One 7, e51845 (2012).
37. N. R. Mahadevan, J. Rodvold, H. Sepulveda, S. Rossi, A. F. Drew, M. Zanetti, Transmission of endoplasmic reticulum stress and pro-inflammation from tumor cells to myeloid cells. Proc. Natl. Acad. Sci. U.S.A. 108, 6561–6566 (2011).
38. N. R. Mahadevan, M. Zanetti, Tumor stress inside out: Cell-extrinsic effects of the unfolded protein response in tumor cells modulate the immunological landscape of the tumor microenvironment. J. Immunol. 187, 4403–4409 (2011).
39. P. Walter, D. Ron, The unfolded protein response: From stress pathway to homeostatic regulation. Science 334, 1081–1086 (2011).
40. P. T. Thevenot, R. A. Sierra, P. L. Raber, A. A. Al-Khami, J. Trillo-Tinoco, P. Zarreii, A. C. Ochoa, Y. Cui, L. Del Valle, P. C. Rodriguez, The stress-response sensor chop regulates the function and accumulation of myeloid-derived suppressor cells in tumors. Immunity 41, 389–401 (2014).
41. B. R. Lee, S. Y. Chang, E. H. Hong, B. E. Kwon, H. M. Kim, Y. J. Kim, J. Lee, H. J. Cho, J. H. Cheon, H. J. Ko, Elevated endoplasmic reticulum stress reinforced immunosuppression in the tumor microenvironment via myeloid-derived suppressor cells. Oncotarget 5, 12331–12345 (2014).
42. D. Hong, Y. P. Bai, H. C. Gao, X. Wang, L. F. Li, G. G. Zhang, C. P. Hu, Ox-LDL induces endothelial cell apoptosis via the LOX-1-dependent endoplasmic reticulum stress pathway. Atherosclerosis 235, 310–317 (2014).
43. D. Hong, L. F. Li, H. C. Gao, X. Wang, C. C. Li, Y. Luo, Y. P. Bai, G. G. Zhang, High-density lipoprotein prevents endoplasmic reticulum stress-induced downregulation of liver LOX-1 expression. PLOS One 10, e0124285 (2015).
44. S. E. Bettigole, L. H. Glimcher, Endoplasmic reticulum stress in immunity. Annu. Rev. Immunol. 33, 107–138 (2014).
45. K. Zhang, R. J. Kaufman, From endoplasmic-reticulum stress to the inflammatory response. Nature 454, 455–462 (2008).
46. H. A. Hirsch, D. Iliopoulos, A. Joshi, Y. Zhang, S. A. Jaeger, M. Bulyk, P. N. Tsichlis, X. Shirley Liu, K. Struhl, A transcriptional signature and common gene networks link cancer with lipid metabolism and diverse human diseases. Cancer Cell 17, 348–361 (2010).
47. J. Lu, S. Mitra, X. Wang, M. Khaidakov, J. L. Mehta, Oxidative stress and lectin-like ox-LDL-receptor LOX-1 in atherogenesis and tumorigenesis. Antioxid. Redox Signal. 15, 2301–2333 (2011).
48. X. Wang, M. I. Phillips, J. L. Mehta, LOX-1 and angiotensin receptors, and their interplay. Cardiovasc. Drugs Ther. 25, 401–417 (2011).
49. J. De Siqueira, I. Abdul Zani, D. A. Russell, S. B. Wheatcroft, S. Ponnambalam, S. Homer-Vanniasinkam, Clinical and preclinical use of LOX-1-specific antibodies in diagnostics and therapeutics. J. Cardiovasc. Transl. Res. 8, 458–465 (2015).
50. J. L. Mehta, M. Khaidakov, P. L. Hermonat, S. Mitra, X. Wang, G. Novelli, T. Sawamura, LOX-1: A new target for therapy for cardiovascular diseases. Cardiovasc. Drugs Ther. 25, 495–500 (2011).
51. S. Zhang, A comprehensive evaluation of SAM, the SAM R-package and a simple modification to improve its performance. BMC Bioinformatics 8, 230 (2007).
52. J. D. Storey, R. Tibshirani, Statistical significance for genomewide studies. Proc. Natl. Acad. Sci. U.S.A. 100, 9440–9445 (2003).